Results 191 to 200 of about 26,895 (263)

SGLT2 Inhibitor Use and Cardiorenal Outcomes in Type 2 Diabetes With Liver Cirrhosis.

JAMA Netw Open
Chung MC, Yu TM, Wu LY, Wu MJ, Shieh JJ, Chung CJ.   +5 more
europepmc   +1 more source

SGLT2 Inhibitor Therapy and Long-Term Outcomes After Transcatheter Aortic Valve Implantation in Patients with Low Ejection Fraction. [PDF]

Medicina (Kaunas)
Keskin B, Hakgor A, Khidolda Y, Dursun A, Akhundova A, Savur U, Olgun FE, Onder O, Gul YG, Cakal B, Demir B, Gunes HM, Karaca IO, Guler E, Boztosun B.   +14 more
europepmc   +1 more source

Comment on ‘Glycemic control and renal function decline in patients with chronic coronary syndrome: A multicenter cohort study’

Journal of Diabetes Investigation, EarlyView.
Jiandi Li
wiley   +1 more source

Effects of Oral Single‐Dose Empagliflozin on Urinary Glucose, Serum β‐Hydroxybutyrate, and Plasma Empagliflozin Concentrations in Healthy Adult Dogs

Journal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT Empagliflozin is a sodium‐glucose cotransporter‐2 inhibitor used for treating humans with heart failure, among other conditions. This drug could have applications in veterinary cardiology, but whether empagliflozin has biological effects in dogs when administered at dosages approximating human therapeutic dosages is unknown.
Andrea D. Plá Gutierrez, M. Lynne O'Sullivan, Etienne Côté, Sandra McConkey, Butch KuKanich, Stephanie E. Martinez   +5 more
wiley   +1 more source

Pharmacokinetics of Bexagliflozin After Intravenous and Oral Administration in Cats

Journal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT Bexagliflozin, a selective sodium–glucose cotransporter 2 (SGLT2) inhibitor, has been developed for feline diabetes mellitus. This study characterized bexagliflozin pharmacokinetics in healthy cats after single intravenous and oral administrations.
Yogini Patel, Sheeva Bhattarai, Céline E. Toutain   +2 more
wiley   +1 more source

Case Report: Euglycemic ketoacidosis in a non-diabetic patient: a rare adverse effect of SGLT2 inhibitor therapy. [PDF]

Front Endocrinol (Lausanne)
Prasad S, Sharma S, Shetty R, Singh S, Parmar V, Shivaprasad C, Dhaduk V.   +6 more
europepmc   +1 more source

Low Weight Loss Response to Incretin Analogs: A Systematic Review

Obesity Reviews, EarlyView.
ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley   +1 more source

The effect of SGLT2 inhibitor and HIF-PHI on the podocyte-specific molecules and cytoskeleton of diabetic podocytes. [PDF]

BMC Nephrol
Li C, Ng JKC, Chan GCK, Fung WWS, Chow KM, Szeto CC.   +5 more
europepmc   +1 more source

SGLT2 independent effects of the SGLT2 inhibitor empagliflozin

This thesis explores how sodium glucose cotransporter 2 inhibitors (SGLT2i), particularly empagliflozin (EMPA), reduce cardiovascular risk by investigating their effects on cardiac infarction, hypertrophy, and heart failure (HF). SGLT2i demonstrate significant cardiovascular benefits across diabetic and non-diabetic populations, possibly through off ...
openaire   +2 more sources

Innovations in Obesity Treatment: Beyond Adipose Tissue Dysfunction

Obesity Reviews, EarlyView.
Obesity drives chronic inflammation, insulin resistance, type 2 diabetes, and cancer development through adipocyte dysfunction. Addressing this multisystemic disorder requires integrated strategies beyond diet and exercise, such as thermogenesis activation via menthol or capsinoids and appetite control through GLP‐1/GIP agonists and neuromodulation to ...
Jesica Martínez‐Godfrey, Irene Pomares‐Bri, Paula de Juan‐Maciá, Mariló Olivares‐Vicente, Enrique Barrajón‐Catalán, Vicente Micol, Enrique Roche, María Herranz‐López   +7 more
wiley   +1 more source